Item 7.01 Regulation FD Disclosure

Lexaria Bioscience Corp. has revised its investor presentation to provide updated information about its research investigating the incorporation of its patented DehydraTECH technology with antiviral drugs.

The full power point presentation is attached as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

© Edgar Online, source Glimpses